TACT : Overview
To date the TACT has held 16 review meetings across Europe and the US, and has reviewed a total of 46 program applications from both academic investigators and industry in the following areas: DMD, BMD, SMA, IBM, CMD, NMD, MNGIE and XLMTM. Of the 46 compounds reviewed 29 were from industry and 17 were from academic applications; 21 were for novel compounds and 25 were for repurposed drugs; 23 were preclinical stage applications and 23 were clinical stage applications. Therefore, TACT believes that it is fulfilling its remit to be an important resource to many different groups at varying stages of the drug development pathway.
All non-confidential summaries from these applications are now available from the TACT section of the TREAT-NMD website.
Looking forward, the dates of the upcoming TACT review meeting(s) have now been confirmed:
2–3 November 2019 – Location to be confirmed
Anyone wishing to submit a proposal for these meetings should contact Cathy Turner from the TACT secretariat, as soon as possible.
TACT and the Secretariat would like to gratefully acknowledge the continued support received from patient organisations which make these meetings possible.
If you wish to find out more about TACT you can view a video of a presentation given by Dr Cristina Csimma and Dr Sharon Hesterlee at the Partnering for Cures – Faster Cures Conference in New York City, November 2012. View video here.